Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in . gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site VSports app下载. .

Https

The site is secure V体育官网. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. .

Clinical Trial
. 2019 Jul;78(7):899-907.
doi: 10.1136/annrheumdis-2018-214827. Epub 2019 Apr 29.

Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

Tsutomu Takeuchi #  1 , Yoshiya Tanaka #  2 , Satoshi Soen  3 , Hisashi Yamanaka  4 , Toshiyuki Yoneda  5 , Sakae Tanaka  6 , Takaya Nitta  7 , Naoki Okubo  8 , Harry K Genant  9 , Désirée van der Heijde  10
Affiliations
Clinical Trial

"V体育官网入口" Effects of the anti-RANKL antibody denosumab on joint structural damage in patients with rheumatoid arthritis treated with conventional synthetic disease-modifying antirheumatic drugs (DESIRABLE study): a randomised, double-blind, placebo-controlled phase 3 trial

Tsutomu Takeuchi et al. Ann Rheum Dis. 2019 Jul.

Abstract

Objective: To evaluate the efficacy of denosumab in suppressing joint destruction when added to conventional synthetic disease-modifying antirheumatic drug (csDMARD) therapy in patients with rheumatoid arthritis (RA) VSports手机版. .

Methods: This was a multi-centre, randomised, double-blind, parallel-group, placebo-controlled phase 3 study in Japan. Patients with RA aged ≥20 years receiving csDMARDs were randomly assigned (1:1:1) to denosumab 60 mg every 3 months (Q3M), denosumab 60 mg every 6 months (Q6M) or placebo. The change in the modified total Sharp score (mTSS) and effect on bone mineral density (BMD) at 12 months was evaluated. V体育安卓版.

Results: In total, 654 patients received the trial drugs. Denosumab groups showed significantly less progression of joint destruction. The mean changes in the mTSS at 12 months were 1. 49 (95% CI 0. 99 to 1. 99) in the placebo group, 0. 99 (95% CI 0. 49 to 1. 49) in the Q6M group (p=0. 0235) and 0. 72 (95% CI 0. 41 to 1. 03) in the Q3M group (p=0. 0055). The mean changes in bone erosion score were 0. 98 (95% CI 0. 65 to 1. 31) in the placebo group, 0. 51 (95% CI 0. 22 to 0. 80) in the Q6M group (p=0. 0104) and 0. 22 (95% CI 0. 09 to 0. 34) in the Q3M group (p=0. 0001). No significant between-group difference was observed in the joint space narrowing score V体育ios版. The per cent change in lumbar spine (L1-L4) BMD in the placebo, Q6M and Q3M groups were -1. 03%, 3. 99% (p<0. 0001) and 4. 88% (p<0. 0001). No major differences were observed among safety profiles. .

Conclusions: Denosumab inhibits the progression of joint destruction, increases BMD and is well tolerated in patients with RA taking csDMARD. VSports最新版本.

Keywords: denosumab; erosion; joint destruction; rheumatoid arthritis. V体育平台登录.

PubMed Disclaimer

Conflict of interest statement

Competing interests: TT has received research grants from AbbVie, Asahi Kasei, Astellas, AYUMI, Chugai, Daiichi Sankyo, Eisai, Mitsubishi Tanabe, Nippon Kayaku, Novartis, Pfizer and Takeda and has received personal fees from AbbVie, Astellas, Astra Zeneca, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eisai, Eli Lilly, GlaxoSmithKline, Janssen, Mitsubishi Tanabe, Nippon Kayaku, Novartis, Pfizer, Sanofi, Taiho, Taisho Toyama, Takeda, Teijin and UCB. YT has received research grants from AbbVie, Astellas, Chugai, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Kyowa Hakko Kirin, Mitsubishi Tanabe, MSD, Ono, Pfizer and Takeda and has received personal fees from Astellas, Bristol-Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, Janssen, Mitsubishi Tanabe, Pfizer, Sanofi, UCB and YL Biologics. SS has received grant/research support from Chugai and Daiichi Sankyo and has received personal fees from Asahi-Kasei Pharma, Astellas, MSD, Chugai, Daiichi Sankyo, Eli Lilly, Mitsubishi-Tanabe, Pfizer, Takeda and Teijin V体育官网入口. HY has received research grants from AbbVie, Astellas, AYUMI, BMS, Chugai, Daiichi Sankyo, Eisai, Kaken, Mitsubishi Tanabe, MSD, Nippon Shinyaku, Ono, Pfizer, Takeda, Teijin, Torii and UCB and has received consulting fees from Astellas, BMS, Chugai, Daiichi Sankyo, Mitsubishi Tanabe, Nippon Kayaku, Pfizer, Takeda, Teijin and YL Biologics. TY has received Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (MEXT #17H04377) and has received consulting fees from Daiichi Sankyo. ST has acted as a consultant for AbbVie, Asahi Kasei Pharma, Amgen, Astellas, Daiichi Sankyo, Eli Lilly, MSD, Ono and Teijin Pharma. TN is an employee of Daiichi Sankyo. NO is a shareholder and employee of Daiichi Sankyo. HKG has received consulting fees from Amgen, Agnovos, Bioclinica, Biomarin, Clementia, Daiichi Sanyo, Eli Lilly, Janssen, Medimmune, Merck, Novartis, Pfizer, Regeneron, Servier and Takeda. DvdH has received consulting fees from AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB and is the director of Imaging Rheumatology BV.

VSports注册入口 - Figures

Figure 1
Figure 1
Trial profile. *As one patient assigned to denosumab Q6M was administered placebo by mistake, the patient was included in the placebo group for safety analysis. †No mTSS measurements available at baseline or after the first administration of treatment. §207 (per-protocol set). ¶202 (per-protocol set). ǂ200 (per-protocol set). mTSS, modified total Sharp score; PRT, protocol; Q3M, every 3 months; Q6M, every 6 months.
Figure 2
Figure 2
Mean changes from the baseline in the radiographic scores by the van der Heijde-modified Sharp method. (A) Modified total Sharp score, (B) modified Sharp erosion score and (C) modified Sharp joint space narrowing score. Missing values were imputed using linear extrapolation/interpolation. Mean and 95% CIs are presented. P values were calculated by two-sided van Elteren stratified rank test adjusting for baseline use of glucocorticoid. BL, baseline; n, number of patients who received ≥1 dose of investigational product and had a baseline and at least one postbaseline measurement of the radiograph score; Q3M, every 3 months; Q6M, every 6 months.
Figure 3
Figure 3
Cumulative probability plots of changes from the baseline in the radiographic score at 12 months. (A) Modified total Sharp score, (B) modified Sharp erosion score and (C) modified Sharp joint space narrowing score. n, number of patients who received ≥1 dose of investigational product and had a baseline and at least one postbaseline measurement of the radiograph score; Q3M, every 3 months; Q6M, every 6 months.
Figure 4
Figure 4
Per cent change in lumbar spinal bone mineral density (BMD) at 12 months from baseline in all patients (A), patients stratified by baseline use of glucocorticoid (B) and patients stratified by osteoporosis status (C). Data are for full analysis set (observed data). Coloured bars show least square mean values. P values are calculated using the analysis of covariance model after adjusting for treatment, baseline value, machine type, baseline value-by-machine type interaction and baseline use of glucocorticoid. Q3M, every 3 months; Q6M, every 6 months.
See this image and copyright information in PMC

Comment in

  • 'DESIRABLE' or not?
    Acharya N, Chattopadhyay A, Dhir V. Acharya N, et al. Ann Rheum Dis. 2021 Aug;80(8):e138. doi: 10.1136/annrheumdis-2019-216236. Epub 2019 Sep 6. Ann Rheum Dis. 2021. PMID: 31492704 No abstract available.

"V体育安卓版" References

    1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016;388:2023–38. 10.1016/S0140-6736(16)30173-8 - "V体育2025版" DOI - PubMed
    1. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet 2017;389:2328–37. 10.1016/S0140-6736(17)31472-1 - DOI - PubMed
    1. Heinlen L, Humphrey MB. Skeletal complications of rheumatoid arthritis. Osteoporos Int 2017;28:2801–12. 10.1007/s00198-017-4170-5 - DOI - PubMed
    1. Gough AK, Lilley J, Eyre S, et al. . Generalised bone loss in patients with early rheumatoid arthritis. Lancet 1994;344:23–7. 10.1016/S0140-6736(94)91049-9 - DOI - PubMed
    1. Yeo L, Lom H, Juarez M, et al. . Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Ann Rheum Dis 2015;74:928–35. 10.1136/annrheumdis-2013-204116 - DOI - PMC - PubMed

"V体育官网入口" Publication types

MeSH terms